Ketabon

In Phase 2 clinical studies, the lead asset KET01—an oral prolonged-release formulation of ketamine—demonstrated statistically significant early improvements in depressive severity versus placebo at Days 4 and 7 in patients with treatment-resistant depression, with minimal dissociative and cardiovascular side effects compared to conventional ketamine therapies. By Day 21, significance versus placebo was not reached, but benefits persisted through follow-up periods. KET01 is considered well-tolerated and could be suitable for at-home use. The company is advancing to pivotal Phase 3 trials for Major Depressive Disorder and Treatment-Resistant Depression, with potential future expansion into additional psychiatric indications[4][2][5][1].